| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -9.5 | -7.3 |
| EPS (diluted, $ a share) | $-0.22 | $-0.37 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: ANVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Annovis Bio, Inc.: key numbers
- Share price
- $0.7500Close, Nov 16
- Market cap
- $46.5M
- Shares outstanding
- 62.02MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Annovis Bio, Inc.
All →Annovis Bio Financial Results
Annovis Bio reported third quarter 2026 financial results and provided a clinical update on its Phase 3 DUET-AD study for Alzheimer's disease, with a data readout expected in March 2027. The company also highlighted a $21.0 million capital raise from an underwritten public offering intended to fund operations through the upcoming clinical milestones.
- Term
- Q3 2026
“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA). We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027. The team is working very hard to deliver clean data and an on-time readout.”
Maria Maccecchini, PhD, President and CEO of Annovis
Annovis Bio Insider Michael B. Hoffman Buys $5M of Stock
Michael B. Hoffman bought 5,000,000 shares of Annovis Bio, Inc. at $1.00 a share, worth $5M in total on Nov 6, 2026. Shares held after the trade: 8,364,883 (+148.6%).
- Value
- $5M
- Shares
- 5,000,000
- Price
- $1.00
- Holding change
- +148.6%
- Trade date
- Nov 6, 2026
Annovis Bio Capital Raise of $21M
Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.
- Value
- $21M
- Counterparty
- Canaccord Genuity LLC
Annovis Bio Business Update
Annovis Bio provided a preliminary estimate of its cash and cash equivalents, which were approximately $2.8 million as of September 30, 2026. The company noted that it has not yet completed its quarterly financial closing processes and the figure is subject to change upon completion of its full interim financial statements.
Annovis Bio Stock Plan Amendment
Annovis Bio stockholders approved an amendment to the 2019 Equity Incentive Plan to increase the number of authorized shares available for issuance. Additionally, stockholders approved a charter amendment to double the company's total authorized common stock from 70 million to 140 million shares.
Annovis Bio Nasdaq/NYSE Compliance Notice
Annovis Bio received a deficiency notice from the NYSE for failing to maintain a minimum average market capitalization of $50 million and stockholders' equity of $50 million over a 30-day period. The company has 45 days to submit a compliance plan and 9 months to regain compliance to avoid delisting. During this period, the stock will continue to trade under the symbol 'ANVS' with an added '.BC' designation.
- Counterparty
- NYSE
- Term
- 9 months